Maple Securities USA’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Maple Securities USA’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-6,579	Closed	-$495K	–	321
2015 Q1	$495K	Buy	+6,579	New	+$460K	0.04%	113

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Maple Securities USA's XBI Position: Q2 2015 in Review

Maple Securities USA sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2015, closing a stake of 6,579 shares — an estimated $495K sold.

Maple Securities USA first reported a position in XBI in Q1 2015 and held it in 1 quarter. The position peaked at $495K in Q1 2015. 193 funds tracked by Wall St. Rank hold XBI as of Q2 2015.

Maple Securities USA reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2015 after selling out during the quarter.
Maple Securities USA sold 6,579 State Street SPDR S&P Biotech ETF shares in Q2 2015, an estimated $495K.
Maple Securities USA first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and held it in 1 quarter.
Maple Securities USA's State Street SPDR S&P Biotech ETF position peaked at $495K in Q1 2015.
193 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2015.

Based on Maple Securities USA's 13F filing for Q2 2015, filed 24 Jul 2015.